Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by
antinuclear antibodies (ANAs) that form immune complexes that mediate pathogenesis by …

SLE is characterised by an activation of the interferon (IFN) system, which leads to an
increased expression of IFN-regulated genes. The reasons behind the IFN signature in SLE …

Summary Systemic Lupus Erythematosus (SLE) is characterized by B cells lacking IgD and
CD27 (double negative; DN). We show that DN cell expansions reflected a subset of CXCR5 …

Highlights•Type I IFN is implicated in SLE pathogenesis by multiple lines of evidence,
including genetics and induction of SLE by IFN treatment.•Nucleic-acid sensing pathways …

Objectives To characterise the efficacy and safety of anifrolumab in patients with systemic
lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic …

The type I interferon pathway has been implicated in the pathogenesis of a number of
rheumatic diseases, including systemic lupus erythematosus, Sjögren syndrome, myositis …

Despite recent improvements in the treatment of systemic lupus erythematosus (SLE),
disease activity, comorbidities and drug toxicity significantly contribute to the risk of …

As the world navigates the coronavirus disease 2019 (COVID-19) pandemic, there is a
growing need to assess its impact in patients with autoimmune rheumatic diseases, such as …

Objectives To examine the safety and efficacy of rontalizumab, a humanised IgG1 anti-
interferon α (anti-IFN-α) monoclonal antibody, in patients with moderate-to-severe systemic …

Abstract Background and aim Interferons (IFNs) are considered to be key molecules in the
pathogenesis of systemic lupus erythematosus (SLE). We measured levels of type I, II and III …